Abstract

Conventional sonodynamic therapy (SDT) is still limited in conquering localized tumors owing to its low reactive oxygen species (ROS)-based therapeutic effect and undesirably inhibiting effect of immunosuppressive tumor microenvironment (ITM). In this study, we reasonably designed a new sonosensitizer, gadolinium (III) porphyrinate (GdPorP), which could efficiently produce ROS upon ultrasound irradiation and specifically accumulate in mitochondria. The GdPorP-based mitochondria-specific sonodamage could induce high-efficiency cell apoptosis and cascade to producing large-scale immunogenic cell death. After GdPorP systematically delivered together with the indoleamine 2,3-dioxygenase (IDO) inhibitor by a pH-sensitive nanomedicine, the localized liver tumor was specifically mapped by the “switching-on” MRI. And the nanomedicine could not only efficiently suppress the progression of primary liver tumors but also simultaneously boost the systematic antitumor immune effect via the inhibition of ITM. The GdPorP-approved sonodynamic-immunotherapy (SDIT) has thereby been established as a new paradigm for upgrading the efficacy of cancer SDT.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call